van den Bent, M, Baumert, B, Erridge, SC, Vogelbaum, MA, Nowak, AK, Sanson, M, Brandes, AA, Clement, PM, Baurain, JF, Mason, WP, Wheeler, H, Chinot, OL, Gill, S, Griffin, M, Brachman, DG
, Taal, W, Ruda, R, Weller, M, McBain, C, Reijneveld, J, Enting, RH, Weber, DC, Lesimple, T, Clenton, S, van Gijtenbeek, A, Pascoe, S, Herrlinger, U, Hau, P, Dhermain, F, Heuvel, I, Stupp, R, Aldape, K, Jenkins, RB
, Dubbink, EJ, Dinjens, W, Wesseling, P, Nuyens, S, Golfinopoulos, V, Gorlia, T, Wick, W & Kros, JM 2017, '
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study',
Lancet (UK), vol. 390, no. 10103, pp. 1645-1653.
https://doi.org/10.1016/S0140-6736(17)31442-3